Krystal Biotech Inc KRYS

US Biotechnology

$341.12 ▼ -7.01% ($-25.73)

⬇️ Below Yest. Low 📅 Earnings This Week

Open $364.66

Prev Close $366.85

Day Range $340.55 – $367.30

52W Range $130.50 – $382.54

Market Cap $10.06B

P/E (TTM) 44.69

Beta 0.54

EPS (TTM) $7.48

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-09-20
Shares Out.	29,480,000
Website	krystalbio.com/ ↗
Phone	13026587581
Employees	295
Revenue	$116.4M
Gross Profit	$110.0M
Net Income	$55.9M
Free Cash Flow	$237.4M
Total Assets	$1.40B
Total Liabilities	$120.2M
Equity	$1.28B

About Krystal Biotech Inc

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Krystal Biotech Inc is a publicly traded company under the ticker symbol KRYS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.